Edition:
India

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

7.20USD
10:03pm IST
Change (% chg)

$-0.09 (-1.23%)
Prev Close
$7.29
Open
$7.25
Day's High
$7.36
Day's Low
$7.03
Volume
6,985
Avg. Vol
40,110
52-wk High
$21.59
52-wk Low
$4.78

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $110.31
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Gemphire Therapeutics Names Steven Gullans CEO

* GEMPHIRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF STEVEN GULLANS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

04 May 2018

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

16 Mar 2018

Earnings vs. Estimates